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Background: Chronic musculoskeletal pain involves connective tissue remodeling triggered by inflammatory
mediators, such as bradykinin. Fibroblast cells signaling involve changes in intracellular Ca2+ ([Ca2+]i). ATP has been
related to connective tissue mechanotransduction, remodeling and chronic inflammatory pain, via P2 purinoceptors
activation. Here, we investigated the involvement of ATP in bradykinin-induced Ca2+ signals in human
subcutaneous fibroblasts.
Results: Bradykinin, via B2 receptors, caused an abrupt rise in [Ca
2+]i to a peak that declined to a plateau, which
concentration remained constant until washout. The plateau phase was absent in Ca2+-free medium; [Ca2+]i signal
was substantially reduced after depleting intracellular Ca2+ stores with thapsigargin. Extracellular ATP inactivation
with apyrase decreased the [Ca2+]i plateau. Human subcutaneous fibroblasts respond to bradykinin by releasing
ATP via connexin and pannexin hemichannels, since blockade of connexins, with 2-octanol or carbenoxolone, and
pannexin-1, with 10Panx, attenuated bradykinin-induced [Ca2+]i plateau, whereas inhibitors of vesicular exocytosis,
such as brefeldin A and bafilomycin A1, were inactive. The kinetics of extracellular ATP catabolism favors ADP
accumulation in human fibroblast cultures. Inhibition of ectonucleotidase activity and, thus, ADP formation from
released ATP with POM-1 or by Mg2+ removal from media reduced bradykinin-induced [Ca2+]i plateau. Selective
blockade of the ADP-sensitive P2Y12 receptor with AR-C66096 attenuated bradykinin [Ca
2+]i plateau, whereas the
P2Y1 and P2Y13 receptor antagonists, respectively MRS 2179 and MRS 2211, were inactive. Human fibroblasts
exhibited immunoreactivity against connexin-43, pannexin-1 and P2Y12 receptor.
Conclusions: Bradykinin induces ATP release from human subcutaneous fibroblasts via connexin and
pannexin-1-containing hemichannels leading to [Ca2+]i mobilization through the cooperation of B2 and P2Y12
receptors.
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Despite its overwhelming size throughout the body,
the connective tissue has been generally overlooked or
misunderstood. It has been considered as relatively su-
perfluous apart from its supporting role amongst more
specialized tissues [1]. It has long been known that scar
tissue is a common cause of chronic musculoskeletal
pain. Evidences have been produced suggesting that
connective tissue may become thicker and less compliant
in patients with chronic pain, possible as a result of chronic
inflammation and fibrosis [2-4]. Therefore, the normal
response to mechanical stretch may be dampened by
disturbance of the viscoelastic properties of the subcuta-
neous connective tissue as a consequence of fibroblast
remodeling promoted by inflammatory mediators, like
neurotrophins, cytokines, peptides, protons, free radicals,
histamine, bradykinin, serotonin, and prostanoids [5]. Since
the subcutaneous connective tissue is richly innervated
by sensory nerve endings, inputs arising from affected
connective tissue may alter pain perception.
Bradykinin is one of the most potent algogenic com-
pounds that is synthesized from inactive precursors,
the kininogens, following tissue injury [6] and by
contracting skeletal muscles (reviewed in [7]). Bradykinin
has been strongly implicated in tissue inflammation [6] and
it is also known to be mitogenic in fibroblasts from the hu-
man foreskin and lung [8,9]. Bradykinin preferentially in-
duces its physiological effects by binding to the B2 receptor
subtype. In intact cells, bradykinin was shown to induce the
activation of phospholipases A2, C and D; the release of
prostaglandins, the accumulation of cyclic AMP and of cyc-
lic GMP, and the mobilization of Ca2+ were demonstrated
(reviewed in [10]). Bradykinin causes a rapid (within 30 s)
translocation of protein kinase C isoforms of all groups
(classical Ca2+-dependent isoform α, new Ca2+-independent
isoform ε, and atypical isoform ζ) from the cytosol to the
plasma membrane [10]. Bradykinin-induced translocation
of protein kinase C to the plasma membrane may favor
enzyme coupling to coexistent extracellular signaling
molecules under pathological conditions, thus significantly
potentiating their effects.
The way bradykinin is involved in pain perception
might involve direct excitation of primary nociceptive
afferents and/or the indirect reduction of nociceptors
threshold by favoring the release of excitatory signaling
mediators [11]. It has been showed that acute bradykinin
exposure potentiates algogenic P2X3 purinoceptor-mediated
calcium responses from neurons, followed by their down-
regulation upon chronic (24 h) exposure. On the other
hand, P2Y receptors responses in satellite neuroglia may
be upregulated, suggesting a complex interplay between
bradykinin and P2 purinoceptors activation in pain
pathophysiology [12]. Previous studies demonstrated
that bradykinin elicits the release of ATP from variouscell types, including smooth muscle fibers, epithelial
cells and cardiac endothelial cells from guinea pigs
[13], urothelial cells from both human and rats [14,15],
and several immortalized cell lines (e.g. MDCK, COS-7,
HEK-293) (reviewed in [16]). The mechanism of ATP re-
lease induced by bradykinin is, however, poorly understood
particularly in human tissues. Nucleotides-releasing
pathways in intact cells include (1) electrodiffusional trans-
location via connexin- and pannexin-containing hemichan-
nels and voltage-dependent anion channels, (2) facilitated
diffusion by nucleotide-specific ATP-binding cassette
(ABC) transporters, and (3) vesicle exocytosis (reviewed
in [17]). In parallel to bradykinin, huge amounts of extracel-
lular ATP may leak from damaged cells during mild tissue
injury. Once released, ATP may act as an autocrine or
paracrine mediator in neighboring cells via ionotropic
P2X and metabotropic P2Y purinoceptors activation.
ATP signaling may, however, be limited by membrane-
bound ectonucleotidases, which sequentially catabolize
nucleoside 5’-triphosphates to their respective 5’-di- and
monophosphates and adenosine [17]. As a consequence,
appearance of ATP and active metabolites, like ADP and
adenosine, in the extracellular fluid form concentration
gradients enabling differential targeting of subtype-specific
purinoceptors and, thus, cell communication and signaling.
Thus, taking into consideration that (1) changes in the
regulation of connective tissue ATP signaling may be im-
portant in the pathogenesis of chronic inflammatory pain
[18] and that (2) algogenic inflammatory mediators, such
as bradykinin, may sensitize cells to autocrine and para-
crine signals operated by extracellular adenine nucleotides
(reviewed in [19]), we investigated the involvement of ATP
in bradykinin-induced Ca2+ signals in human subcutaneous
fibroblasts. Understanding the mechanisms underlying
purinergic cell signaling and its interplay with inflam-
matory mediators in the human subcutaneous con-
nective tissue may highlight new strategies for the
treatment of chronic musculoskeletal painful diseases
(e.g. drug-resistant fibromyalgia).
Results
Characterization of human fibroblast cells in culture
Cultured cells obtained from human subcutaneous
connective tissue through the explant technique are
elongated and exhibit a spindle-shape morphology,
which is characteristic of fibroblasts [20]. At the time
that functional experiments were conducted, all cells
exhibited positive immunoreactivity against fibroblast-cell
markers, vimentin (Figure 1Ai, red) and type I collagen
(Figure 1Ai, green) [21], and no specific staining was devel-
oped against stress fibers containing α-smooth muscle actin
(SMA-FITC, Figure 1Aii). Negative controls, in which cells
were incubated only with the secondary antibodies Alexa
Fluor 488 (green) and Alexa Fluor 568 (red), are shown in
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Figure 1 Bradykinin stimulates the release of intracellular Ca2+ stores and Ca2+ influx from the extracellular space. Panel A shows
immunoreactivity of cells cultured from explants of human subcutaneous tissue against fibroblast-cell markers, vimentin (red, Ai) and type I
collagen (green, Ai), and α-smooth muscle actin (SMA-FITC, green, Aii). Negative controls, in which cells were incubated only with secondary
antibodies, Alexa Fluor 488 (green) and Alexa Fluor 568 (red), are shown for comparison purposes (Aiii); a positive control of SMA-FITC
immunoreactivity in rat cardiac myofibroblasts is also shown (green, Aiv). Cell nuclei are stained with DAPI (blue); scale bar 60 μm. Panel B
illustrates intracellular Ca2+ ([Ca2+]i) oscillations in cultured human subcutaneous fibroblasts loaded with the fluorescent calcium indicator, Fluo-4
NW (2.5 μM, see Methods) obtained in the absence and in the presence of bradykinin (BK, 30 μM). Changes in fluorescence were detected in the
time-lapse mode with a confocal microscope. Calibration to the maximal calcium load produced by ionomycin (5 μM, 100% response) is also
shown for comparison. Image scale bars: 30 μm. Panel C shows that the kinetics of BK-induced [Ca2+]i signals differed slightly between cells of a
given population. Panel D depicts the concentration-response curve of [Ca2+]i oscillations produced by BK (0.003-100 μM). Panels E, F and G,
represent [Ca2+]i oscillations produced by BK (30 μM) applied in the absence (E) and in the presence of the selective endoplasmic reticulum
Ca2+-ATPase inhibitor, thapsigargin (2 μM, F), and after removal of extracellular Ca2+ (Ca2+-free medium plus EGTA, 100 μM, G). Black arrows
indicate the time of drugs application. Each point represents pooled data from an n number of experiments. The vertical bars represent S.E.M..
*p < 0.05 represent significant differences from BK (30 μM) alone.
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illustrates a positive control of SMA-FITC obtained
in rat cardiac myofibroblasts where SMA-immunoreactivity
exhibits a clear filamentary pattern (Figure 1Aiv), which
was not observed in human subcutaneous fibroblasts
(Figure 1Aii).Bradykinin, via B2 receptors, stimulates the release of
intracellular Ca2+ stores and Ca2+ influx from the
extracellular space
Bradykinin (0.001-100 μM) caused prominent intracellular
Ca2+ ([Ca2+]i) rises in human subcutaneous fibroblasts
(Figure 1). Global changes in [Ca2+]i were monitored with
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of the cells with the calcium sensitive dye, Fluo-4 NW;
in some instances, single-cell [Ca2+]i imaging was also
performed using a laser scanning confocal microscope in
the time-lapse mode (Figure 1B and 1C) [22]. The effect of
bradykinin (0.001-100 μM) was dependent on the concen-
tration (Figure 1D); significant (p < 0.05) [Ca2+]i rises were
observed at concentrations higher than 1 μM. Bradykinin
typically produced a biphasic response (Figure 1C); at
30 μM concentration, [Ca2+]i raised abruptly to a peak that
attained 44 ± 2% of the maximal calcium load produced by
ionomycin (5 μM, 100% response), then declined to a plat-
eau of elevated [Ca2+]i which remained fairly constant until
drug washout (Figure 1E). Bradykinin (30 μM) produced
negligible changes in [Ca2+]i in the presence of the se-
lective inhibitor of endoplasmic reticulum Ca2+-ATPase,
thapsigargin (2 μM, n = 5), which is known to deplete intra-
cellular Ca2+ stores following a transient (< 2 min) rise of
[Ca2+]i levels [23] (Figure 1F). Removal of external Ca
2+
(plus EGTA, 100 μM, n = 6) significantly (p < 0.05) attenu-
ated the plateau phase, but the magnitude of the peak was
kept almost unchanged (Figure 1G). It, thus, appears that
in human subcutaneous fibroblasts the initial transient
component must be caused by intracellular Ca2+ release
from internal stores. The sustained plateau of elevated
[Ca2+]i results from Ca
2+ entry through the plasma
membrane in response to depletion of Ca2+ stores and/or
through the concurrent activation of other membrane-
bound receptors, namely P2 purinoceptors. This pattern is
consistent with previous findings in the literature regarding
bradykinin-induced [Ca2+]i responses in several cell types
[24,25], including human fibroblasts of the foreskin [26].
Bradykinin-induced [Ca2+]i rise in human subcutaneous
fibroblasts was concentration-dependently attenuated by
the selective B2 receptor antagonist, HOE-140 (1 and
10 μM, n = 7) (Figure 2B and 2C), whereas selective
blockade of the B1 receptor with R715 (1 μM, n = 4) was
without effect (Figure 2A). At the highest concentration
(10 μM), HOE-140 significantly (p < 0.05) decreased, but
did not completely block, the late phase of bradykinin-
induced [Ca2+]i response given that the peptide was used in
a concentration (30 μM) near that necessary for saturation
of B2 receptors in these cells (see Figure 1D). On their own,
the two antagonists were devoid of any significant effect.
Bradykinin induces ATP release from human subcutaneous
fibroblasts: involvement of intracellular Ca2+ stores
The release of ATP from human subcutaneous fibroblasts
in culture was inferred from destaining of cells loaded with
quinacrine, an ATP-binding intracellular fluorescent dye, by
confocal microscopy in the time-lapse mode. Bradykinin
(30 μM, n = 35) increased (p < 0.05) fluorescence intensity
decay of cells loaded with quinacrine as compared to the
control situation in which the cells were challenged withthe Tyrode’s solution (Figure 3A and 3B). Quinacrine
destaining of cells exposed to bradykinin was more evident
at the periphery than near the nucleus (Figure 3A).
Confirmation that human subcutaneous fibroblasts release
ATP in response to bradykinin (30 μM, n = 4) was obtained
by measuring the luminescence of the medium before
and after bradykinin application to cells incubated with
luciferin-luciferase (Figure 3C). Results demonstrate that
ATP release peaked at 30 s after bradykinin (30 μM)
application and was kept fairly constant during the 4-min
drug application.
Pretreatment with thapsigargin (2 μM, n = 6) signifi-
cantly (p < 0.05) attenuated bradykinin-induced quinacrine
destaining (Figure 3Di). In contrast, removal of extracellular
Ca2+ (plus EGTA, 100 μM, n = 8) from the incubation
medium did not significantly (p > 0.05) affect the fluores-
cence intensity decay of quinacrine stained ATP granules
(Figure 3Dii). These observations indicate that Ca2+ recruit-
ment from thapsigargin-sensitive internal stores is required
for the release of ATP induced by bradykinin.
ATP release via connexin and pannexin-1 hemichannels
contributes to bradykinin-induced [Ca2+]i mobilization
Among other mechanisms, hemichannels containing
connexins (Cx) and pannexin-1 (Panx1) are now widely
accepted as putative mediators of ATP translocation to the
extracellular milieu in non-excitable cells. The expres-
sion of Cx43 is characteristic of fibroblasts from mul-
tiple tissue origins [27,28]. Using immunofluorescence
confocal microscopy (Figure 4Ai) and Western blot ana-
lysis (Figure 4Aii), we demonstrated that fibroblasts of the
human subcutaneous tissue in culture express anti-Panx1
(~50 kDa) immunoreactivity in addition to the expected
Cx43 (43 kDa). Panx1 and Cx43 are both expressed in
relatively high density as compared to β-tubulin standard
protein levels (Figure 4Aiii).
These findings prompted us to test whether bradykinin-
induced [Ca2+]i oscillations in human subcutaneous
fibroblasts depend on the release of ATP via hemichannels
using subtype selective connexin and pannexin-1 inhibitors.
Inhibition of Cx36- and Cx50-containing hemichannels
with mefloquine (MFQ, 3 μM, n = 8) [29,30] was devoid of
effect on bradykinin-induced [Ca2+]i rise (Figure 4Bi). On
the other hand, 2-octanol (1 mM, n = 6), which blocks
Cx43, Cx46 and Cx50 hemichannels [30,31] (Figure 4Bii),
and carbenoxolone (CBX, 300 μM, n = 5), a non-selective
inhibitor of connexins Cx26, Cx30, Cx32, Cx43 and Cx46,
which also blocks Panx1-containing hemichannels [31]
(Figure 4Biii), significantly (p < 0.05) attenuated [Ca2+]i
response induced by bradykinin (30 μM). Interestingly,
the selective Panx1 mimetic inhibitory peptide, 10Panx
(100 μM, n = 6) [32], also decreased the bradykinin-induced
[Ca2+]i response (Figure 4Biv). CBX (300 μM) was the most
effective of the three inhibitors, probably because it has a
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Figure 2 Bradykinin-induced [Ca2+]i rise in human subcutaneous fibroblasts depends on B2 receptor activation. Calcium oscillations in
human fibroblasts of the subcutaneous tissue stimulated with bradykinin (BK, 30 μM) were tested after pretreatment of the cells with selective B1
and B2 receptor antagonists, respectively R715 (1 μM, A) and HOE-140 (1 μM, B; 10 μM, C). Cells were pre-incubated with the cell-permeant
fluorescent calcium indicator, Fluo-4 NW (2.5 μM, see Methods). Changes in fluorescence were detected using a microplate reader. Intracellular
Ca2+ transients were calibrated to the maximal calcium load produced by ionomycin (5 μM, 100% response). Black arrows indicate the time of
drugs application. No changes in baseline fluorescence were observed after application of the antagonists. Each point represents pooled data
from an n number of experiments. The vertical bars represent S.E.M.. *p < 0.05 represent significant differences from BK (30 μM) alone.
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and Panx1 containing hemichannels. Coincidently or not,
2-octanol (1 mM), CBX (300 μM) and 10Panx (100 μM),
were more effective in depressing the plateau phase of
bradykinin (30 μM) response (Figures 4Bii-4Biv), although
2-octanol (1 mM) and CBX (300 μM) also inhibited
(p < 0.05) the fast [Ca2+]i rise induced by the peptide.
Confocal microscopy studies demonstrated that 10Panx
(100 μM) also attenuated (p < 0.05) bradykinin (30 μM)-
induced ATP release from human fibroblasts loaded with
quinacrine (see Figure 3Diii).
In order to test if bradykinin-induced [Ca2+]i oscillations
involved nucleotides-release by exocytosis we used the
vesicular transport inhibitor, brefeldin A (BFA, Figure 4Bv),
and the specific inhibitor of H+-ATPases of the vacuolar
type, bafilomycin A1 (Baf A1, Figure 4Bvi). No statistical
significant (p > 0.05) differences were found in [Ca2+]i
oscillations produced by bradykinin (30 μM) in the absence
and in the presence of BFA (20 μM, n = 4) and Baf A1
(3 μM, n = 7). Confocal microscopy experiments with
primary cultures of rat subcutaneous fibroblasts loaded
with the calcium sensitive dye, Fluo-4 NW, and then
incubated with FM4-64, a membrane-selective fluorescent
dye, were used to evaluate vesicle endocytosis and exo-
cytosis in the time lapse mode [33,34]. Results depicted
in Figure 4Ci, show that bradykinin (30 μM)-induced
[Ca2+]i oscillations were not accompanied by measurable
changes in FM4-64 fluorescence signals in the same cells
(Figure 4Cii). Ionomycin (5 μM) increased moderately FM4-
64 fluorescence labeling because plasma membrane modifi-
cations (e.g. membrane protrusions, microvesiculation,
blebbing) are likely to occur in the presence of the
Ca2+ ionophore. Overall, our findings suggest that ATP
release via connexins (most probable Cx43) and Panx1hemichannels, rather than by vesicle exocytosis, may
contribute importantly to the plateau phase of bradykinin-
induced [Ca2+]i response in fibroblasts cultured from the
human subcutaneous connective tissue.
The plateau phase of bradykinin [Ca2+]i recruitment is
partially dependent on the activation of ADP-sensitive
P2Y12 purinoceptors
Extracellular inactivation of ATP directly into AMP with
apyrase (NTPDase1 or CD39, 2 U/mL, n = 8) reduced
significantly (p < 0.05) the plateau phase of bradykinin
(30 μM, n = 17) response, while keeping fairly conserved
the magnitude of the initial [Ca2+]i rise (Figure 5Ai).
Surprisingly, inhibition of membrane-bound NTPDases
with POM-1 (20 μM, n = 11) [35] also decreased the plat-
eau phase of bradykinin-induced [Ca2+]i response in human
subcutaneous fibroblasts (Figure 5Aii). The result obtained
with POM-1 (20 μM) was confirmed when we tested the
effect of bradykinin on [Ca2+]i oscillations in the ab-
sence of Mg2+, an ion that must be present in millimolar
concentration in the extracellular fluid for maximum ac-
tivity of ectonucleotidases [17] (Figure 5Aiii). These find-
ings provide the first evidence that the plateau phase of
bradykinin-induced [Ca2+]i accumulation by human
subcutaneous fibroblasts requires the release of ATP and
its subsequent conversion into other biologically active
metabolites, most probably ADP, by ectonucleotidases.
The kinetics of the extracellular catabolism of adenine
nucleotides (ATP, ADP and AMP) and formation of me-
tabolites in fibroblasts cultured from the human subcuta-
neous tissue is shown in Figure 5B. Average half-lives of
ATP, ADP and AMP were respectively 12.6 ± 4.2 min,
27.0 ± 1.6 min and 1.5 ± 0.2 min (n = 4 observations from
two individuals), when the substrates were used in a 3 μM
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Figure 3 Bradykinin elicits ATP release from human fibroblasts by a mechanism depending on intracellular Ca2+ mobilization. Panels A,
B and D represent cells loaded with quinacrine (30 μM, a fluorescent dye that specifically binds ATP), for 60 min at 37°C. ATP release was
detected by single-cell confocal microscopy in the time-lapse mode measuring the fluorescence intensity decay 4 min after bradykinin
(BK, 30 μM, A and B) application as compared to the control situation, in which only Tyrode’s solution was applied (A). Panel D, shows the effect
of BK (30 μM) after pretreatment of the cells with the selective endoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin (2 μM, Di), and after
removal of extracellular Ca2+ (Ca2+-free medium plus EGTA, 100 μM, Dii); the effect of BK (30 μM) in the presence of the selective Panx1 inhibitor,
10Panx (100 μM, Diii), is also shown. Image scale bars: 30 μm. Graphs show quinacrine fluorescence decay (arbitrary units, a.u.) plotted versus time
in the presence of Tyrode’s solution (B), thapsigargin (2 μM, Di) and Ca2+-free medium (Dii). Black arrows indicate the time of drugs application.
Each point represents pooled data from an n number of cells. The vertical bars represent S.E.M.. Panel C, shows the ATP content in human
subcutaneous fibroblast cultures at given time intervals (0-240 seconds) in the presence of BK (30 μM, open bars) as compared to the control
condition where only Tyrode’s solution was applied (closed bars). Relative luminescence units (RLUs) were calibrated using a 4 nM ATP standard
(left hand-side black vertical bar). Each bar represents pooled data from an n number of experiments. The vertical bars represent S.E.M.. *p < 0.05
represent significant differences from BK (30 μM) alone.
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http://www.biosignaling.com/content/11/1/70concentration. ATP (3 μM) was sequentially metabolized
into ADP, adenosine (ADO), inosine (INO) and hypoxan-
thine (HX) (Figure 5B). AMP (3 μM) was rapidly and
sequentially converted into ADO and INO respectively
by ecto-5’-nucleotidase (CD73) and adenosine deaminase
(ADA), which might explain why AMP accumulation was
almost negligible when ATP (3 μM) and ADP (3 μM) were
used as substrates.
The analysis of the corresponding half-life time values
clearly indicates that the extracellular catabolism of ADP
into AMP is the rate-limiting step to generate ADO from
exogenously added adenine nucleotides in cultured human
subcutaneous fibroblasts. Therefore, transient accumulation
of ADP in the cultures is in favor of a preferential activationof ADP-sensitive P2Y purinoceptors. To investigate the
contribution of ADP-sensitive P2Y purinoceptors activation
to bradykinin (30 μM)-induced [Ca2+]i response in human
subcutaneous fibroblasts, we tested its effect in the pres-
ence of selective P2Y1, P2Y12 and P2Y13 receptors antago-
nists (Figure 5C). Selective blockade of the P2Y12 receptor
with AR-C 66096 (0.1 μM, n = 6) significantly (p < 0.05)
attenuated the plateau phase of [Ca2+]i rise caused by
bradykinin (30 μM, n = 20) without much affecting the
magnitude of the initial [Ca2+]i rise (Figure 5Cii). No
significant differences (p > 0.05) were observed in the
presence of MRS 2179 (0.3 μM, n = 10) and MRS 2211
(10 μM, n = 10) which selectively antagonize P2Y1 and
P2Y13 receptors, respectively (Figure 5Ci and 5Ciii).
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Figure 4 Bradykinin-induced [Ca2+]i signals in human subcutaneous fibroblasts involve connexin and pannexin-1 containing hemichannels
opening. Panel A shows representative confocal micrographs (Ai) and blots (Aii) of Cx43 and Panx1 hemichannels immunoreactivity in cultured human
subcutaneous fibroblasts from 3-4 individuals. Image scale bars: 60 μm. β-tubulin was used as a reference protein to determine the relative density of
Cx43 and Panx1 immunoblots (Aiii). Panel B shows the effect of bradykinin (BK, 30 μM) in the presence of inhibitors of connexin and/or Panx1
hemichannels, namely mefloquine (MFQ, 3 μM, Bi), 2-octanol (1 mM, Bii), carbenoxolone (CBX 300 μM, Biii) and 10Panx (100 μM, Biv). The effects of the
vesicular transport inhibitor, brefeldin A (BFA, Bv) and of the specific inhibitor of vacuolar H+-ATPases, bafilomycin A1 (Baf A1, Bvi), are also shown for
comparison. Cells were pre-incubated with the cell-permeant fluorescent calcium indicator, Fluo-4 NW (2.5 μM, see Methods). Changes in fluorescence
were detected using a microplate reader. [Ca2+]i transients were calibrated to the maximal calcium load produced by ionomycin (5 μM, 100% response).
Black arrows indicate the time of drugs application. None of the inhibitors significantly change baseline fluorescence when applied alone. Each point
represents pooled data from an n number of experiments. The vertical bars represent S.E.M.. *p< 0.05 represent significant differences from BK (30 μM)
alone. Panel C shows representative traces of single-cell [Ca2+]i oscillations in rat subcutaneous fibroblasts loaded with Fluo-4 NW (Ci) obtained in parallel
with the incorporation of the membrane-selective fluorescent dye, FM4-64 (Cii), used to evaluate vesicle endocytosis and exocytosis in living cells.
Changes in fluorescence were detected in the time-lapse mode using a laser-scanning confocal microscope. Vertical lines indicate the time of drugs
application. Fluorescence confocal micrographs were obtained at the indicated time points (a, b and c). Image scale bars: 30 μm.
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Figure 5 Bradykinin-induced [Ca2+]i mobilization is partially dependent on the activation of P2Y12 purinoceptors. Panel A shows the
effect of bradykinin (BK, 30 μM) after pretreating human subcutaneous fibroblasts with apyrase (2 U/mL, Ai), which catabolizes ATP/ADP into
AMP, and after inhibition of ectonucleotidases, with POM-1 (20 μM, Aii) or after removing Mg2+ from the incubation fluid (Aiii). Panel C shows
the effects of BK (30 μM) in the absence or presence of selective P2Y1, P2Y12 and P2Y13 receptor antagonists, respectively MRS 2179 (0.3 μM, Ci),
AR-C 66096 (0.1 μM, Cii) and MRS 2211 (10 μM, Ciii). Cells were pre-incubated with the cell-permeant fluorescent calcium indicator, Fluo-4 NW
(2.5 μM, see Methods). [Ca2+]i transients were calibrated to the maximal calcium load produced by ionomycin (5 μM, 100% response). Black
arrows indicate the time of drugs application. No changes in baseline fluorescence were observed after application of the modulators. Each point
represents pooled data from an n number of experiments. The vertical bars represent S.E.M.. *p < 0.05 represent significant differences from BK
(30 μM) alone. Panel B illustrates the time course of the extracellular catabolism of adenine nucleotides in human subcutaneous fibroblasts
grown in culture for 11 days. ATP, ADP or AMP (3 μM) were added to the culture medium at time zero; samples (75 μl) were collected at
indicated times. Each sample was analyzed by HPLC to separate and quantify ATP (white), ADP (black), AMP (grey), adenosine (ADO, red), inosine
(INO, orange) and hypoxanthine (HX, green). Each point represents pooled data from two individuals; 2 replicas were performed for each
individual. The calculated half-life time (t½) for each initial substrate is shown for comparison. Panel D shows immunoreactivity of human
subcutaneous fibroblasts against the P2Y12 receptor; shown image is representative of three independent experiments. Image scale bar is 30 μm.
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subcutaneous fibroblasts. The expression of the P2Y12
receptor in cultured human subcutaneous fibroblasts was
confirmed by immunocytochemistry (Figure 5D).
Adenine nucleotides, but not adenosine, increase the
influx of Ca2+ in human subcutaneous fibroblasts
Changes in [Ca2+]i in human subcutaneous fibroblasts
treated with adenine nucleotides (1 mM) in the presence
and in the absence of extracellular Ca2+ are shown in
Figure 6A. Exogenous application of ATP and ADP (1 mM)
transiently increased intracellular [Ca2+]i reaching, respect-
ively, 43 ± 4% (n = 8) and 25 ± 8% (n = 3) of the maximal
calcium load caused by ionomycin (5 μM, 100% response)
within 20 sec from drug application. In Ca2+-free medium
(plus EGTA, 100 μM), ATP- and ADP-induced [Ca2+]i
transients were partially but significantly (p < 0.05) at-
tenuated (Figure 6A).
Adenosine (ADO) is a recognized anti-nociceptive agent
(see e.g. [36]) and plays prominent roles in fibroblasts pro-
liferation and tissue remodeling in the skin, liver and lung
(reviewed in [37]), yet contradictory effects of the nucleo-
side have been described on cardiac fibroblasts ([38,39]).
Given the high amounts of ADO accumulating in cultured
fibroblasts of the human subcutaneous tissue as a result of
the extracellular catabolism of released adenine nucleotides
(see Figure 5), we sought to investigate the contribution
of the nucleoside to bradykinin-induced Ca2+ signals in
these cells. To this end, we used the enzymatically stable
adenosine analogue, 5’-(N-ethylcarboxamide) adenosine
(NECA), which non-selectively activates all four adenosine
receptor subtypes in the submicromolar range. NECA
(10 μM, n = 6) had a negligible effect on [Ca2+]i in
human subcutaneous fibroblasts when it was applied
either alone (Figure 6Bii) or in the presence of bradykinin
(30 μM, n = 5) (Figure 6Biii). No statistical significant
(p > 0.05) difference was found in [Ca2+]i oscillations
caused by bradykinin (30 μM) in the presence of NECA
(10 μM, n = 6) (Figure 6Bii) as compared to the control
situation (Figure 6Bi). Moreover, pretreatment of the cells
with the non-selective adenosine receptor antagonist,
8-phenyltheophylline (8-PT, 2.5 μM, n = 5), was devoid
of effect on bradykinin-induced [Ca2+]i rise (Figure 6C),
suggesting that adenosine has a minor effect on Ca2+
signaling operated by bradykinin in human subcutaneous
fibroblasts.
Discussion
Bradykinin is produced within the interstitium of most
tissues and plays an important role in normal and
pathological conditions, being considered an important
inflammatory pain mediator (reviewed in [40]) that is
associated with chronic musculoskeletal pain syndromes
[41,42]. Recent findings have shown that in the centralnervous system bradykinin triggers astrocyte-neuron signal-
ing via glutamate release followed by NMDA receptors
activation [43]. In peripheral tissues, bradykinin recep-
tors have already been described in sensory neurons of
dorsal root ganglia (DRG), where it exerts direct and
indirect effects via neuronal excitation and threshold
modulation by the release of excitatory signaling mole-
cules, respectively [11]. To the best of our knowledge, this
is the first report demonstrating that fibroblasts isolated
from the human subcutaneous connective tissue respond
to bradykinin by releasing ATP into the extracellular
medium through the activation of B2 receptors, which are
constitutively expressed in most of the tissues exhibiting
bradykinin sensitivity. Although our experiments were
conducted in non-stressful conditions, the involvement
of inducible B1 receptors mediating bradykinin effects in
human subcutaneous fibroblasts cannot be ruled out [44].
Bradykinin-induced ATP release from these cells was
demonstrated by two distinct experimental approaches:
the luciferin-luciferase bioluminescence assay and ATP-
binding quinacrine dye destaining by time-lapse confocal
microscopy. Our data also suggest that bradykinin-induced
ATP release from human subcutaneous fibroblasts requires
Ca2+ recruitment from thapsigargin-sensitive internal
stores and occurs independently of extracellular Ca2+
by electrodiffusional translocation of the nucleotide via
hemichannels containing connexins (most probably Cx43)
and Panx1.
In several cell types [24,25], including human fibroblasts
of the foreskin [26], bradykinin elicits an abrupt rise in
[Ca2+]i to a peak that depends on Ca
2+ recruitment from
internal stores, which then declines to a plateau that is
sustained by Ca2+ entry from the extracellular compart-
ment. The long lasting elevation of [Ca2+]i seen after the
initial [Ca2+]i peak probably results from a receptor- or
second messenger-operated Ca2+ current activated by
bradykinin, rather than via a capacitative pathway [26].
Here, we demonstrate for the first time that ADP-sensitive
P2Y12 purinoceptors may be, at least in part, responsible
for the Ca2+ influx that is characteristic of the plateau phase
of elevated [Ca2+]i caused by bradykinin in human sub-
cutaneous fibroblasts. This conclusion is supported by
results showing that: (1) human subcutaneous fibroblasts
exhibit P2Y12 receptor immunoreactivity, (2) bradykinin in-
duces the release of ATP that is subsequently hydrolyzed
into ADP by membrane-bound ectonucleotidases, (3)
ADP has a tendency to accumulate transiently in the
cultures, given that we found that the extracellular ca-
tabolism of ADP into AMP is the rate-limiting step of
the ectonucleotidase cascade, and, finally, (4) adenine
nucleotides-induced [Ca2+]i rises in human subcutane-
ous fibroblasts are dependent on extracellular Ca2+.
The pathways underlying bradykinin-induced long
lasting Ca2+ influx resulting from the cooperation with
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A Figure 6 Adenine nucleotides, but not adenosine, increase Ca2+
influx from the extracellular space in human subcutaneous
fibroblasts. In panel A, human subcutaneous fibroblasts were
incubated with 1 mM ATP or ADP in control conditions and in Ca2
+-free medium (plus EGTA, 100 μM). Each bar represents pooled
from an n number of experiments. The vertical bars represent S.E.M..
*p < 0.05 represent significant differences compared with the effect
of ATP or ADP alone. Panel B illustrates [Ca2+]i oscillations caused by
5’-(N-ethylcarboxamide) adenosine (NECA, 10 μM), an enzymatically
stable non-selective adenosine receptor agonist, compared with the
effect of bradykinin (BK, 30 μM) in fibroblasts of the human
subcutaneous tissue (Bi). NECA (10 μM) and BK (30 μM) were
applied cumulatively in sequence (Bii) and in the reverse mode
(Biii). Panel C shows BK (30 μM)-induced [Ca2+]i oscillations in the
absence and in the presence of a non-selective adenosine receptor
antagonist, 8-phenyltheophylline (8-PT, 2.5 μM). Cells were
pre-incubated with the cell-permeant fluorescent calcium indicator,
Fluo-4 NW (2.5 μM, see Methods). Changes in fluorescence were
detected using a microplate reader. [Ca2+]i transients were calibrated
to the maximal calcium load produced by ionomycin (5 μM, 100%
response). Black arrows indicate the time of drugs application. No
changes in baseline fluorescence was observed after application of
8-PT (2.5 μM). Each point represents pooled data from an n number
of experiments. The vertical bars represent S.E.M..
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investigated. Interestingly, bradykinin causes a rapid
translocation of all protein kinase C isoforms from the
cytosol to the plasma membrane within the time frame
(30 s) of ATP appearance in the cultures [10], which
may favor the synergism between B2 and P2Y12 receptors
activation. The involvement of ADP-sensitive P2Y12 recep-
tors in neuropathic pain, has been already reported; authors
suggested that this could be due to an unclear mechan-
ism involving non-neuronal cells, such as spinal microglia
[45,46] and trigeminal ganglion satellite cells [47]. The close
proximity between P2Y12 receptor-expressing fibroblasts of
the subcutaneous tissue and sensory nerve fibers exhibiting
numerous ligand-gated receptors (including ionotropic
P2X and metabotropic P2Y purinoceptors) implies that
adenine nucleotides released from stimulated fibro-
blasts may alter acute and chronic pain perception.
During acute tissue injury, excessive ATP release from
damaged fibroblasts, keratinocytes, blood vessels and
inflammatory cells may cause pain by activating exci-
tatory purinoceptors on nociceptive sensory nerve
endings [46,48-50]. Lower levels of ATP released from
intact cells in response to mild mechanical and ther-
mal stimulation may participate in normal tactile sen-
sation and also contribute to the spontaneous pain
and tactile hypersensitivity that occurs under chronic
painful conditions involving the subcutaneous con-
nective tissue when nerve endings become sensitized
[48,51]. We, now, postulated a new type of interaction
involving an autocrine action of ATP, via P2Y12 receptors,
triggered by the activation of bradykinin B2 receptors
in human subcutaneous fibroblasts. Moreover, increased
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blasts from patients affected with systemic sclerosis [52].
Little is known about the mechanisms upstream the
nucleotide release from human fibroblasts despite the im-
portance of connective tissue ATP signaling in the patho-
genesis of acute and chronic inflammatory pain [18,19].
Multiple nucleotide-releasing pathways have been
identified in intact cells, which represent a critical
component for the initiation of the purinergic signaling
cascade (reviewed by [19]). Experiments designed to
manipulate exocytosis of vesicles/organelles containing
compartmentalized ATP suggest that it might not rep-
resent an important pathway for releasing ATP from
human fibroblasts stimulated with bradykinin. Several
non-vesicular ATP release mechanisms have been pro-
posed, yet many remain controversial and are complicated
by the non-specificity of available inhibitors. Hemichannels
possessing connexin and Panx1 subunits represent an
important mechanism for the cellular release of ATP.
The opening of hemichannels occurs in response to
many physiological and pathological situations, including
volume regulation, proliferation, calcium wave propagation
by extracellular messengers and cell death during metabolic
inhibition (reviewed in [53]). Using immunofluorescence
confocal microscopy and Western blot analysis, we demon-
strated that fibroblasts of the human subcutaneous tissue
exhibit strong anti-Panx1 immunoreactivity in addition
to Cx43 that is characteristic from fibroblasts of other
tissue origins [27,28]. Moreover, functional data using non-
selective connexin inhibitors targeting Cx43 hemichannels
(e.g. 2-octanol, CBX) strongly depressed the plateau phase
of bradykinin-induced [Ca2+]i response. Because connexin
hemichannels are activated by moderate (< 500 nM) [Ca2+]i
elevations, these channels may open in response to bradyki-
nin during the initial [Ca2+]i rise [54] and contribute to
ATP release and to the subsequent purinoceptor-mediated
signaling. Closing of connexin containing hemichan-
nels, which unlike Panx1 hemichannels seal when the
spike amplitude rises above 500 nM, contributes to shape
bradykinin-induced [Ca2+]i oscillations as demonstrated by
the partial reduction of the initial [Ca2+]i rise of bradykinin
in the presence of 2-octanol and CBX.
Considering the relatively high potency of CBX (300 μM)
and the fact that this compound also blocks Panx1
containing hemichannels [31], we tested the effect of
the selective Panx1 mimetic inhibitory peptide, 10Panx,
which also depressed the plateau phase of the bradykinin-
induced [Ca2+]i response in parallel to the decline of ATP
release from fibroblasts loaded with quinacrine. Like
the effects obtained with apyrase and with the selective
P2Y12 antagonist, AR-C 66096, inhibition of hemichannels
containing Cx43 and Panx1 were more effective in depress-
ing the plateau phase rather than the peak of the bradykinin
response. Taken together, data suggest that Cx43 and Panx1containing hemichannels have a predominant role on
ATP release from human subcutaneous fibroblasts
stimulated with bradykinin, thereby instigating the re-
generative propagation of intracellular Ca2+ signals.
Our findings agree with the observation that mechanically
stimulated cardiac fibroblasts release ATP in a CBX-
sensitive manner, an effect that the authors attributed to
Cx43 hemichannels not excluding a possible involvement
of Panx1 containing hemichannels [55].
Regardless of whether channel-mediated efflux or vesicle
exocytosis comprises the predominant ATP release mech-
anism, most studies (but not all, see e.g. [56]) have identified
elevation of cytosolic Ca2+ as an important regulator of
nucleotide export in different cell model systems. The
molecular mechanism by which bradykinin releases ATP
through the opening of Cx43 and Panx1 hemichannels in
human subcutaneous fibroblasts may be the generation
of inositol trisphosphate (IP3) by phospholipase C and
the downstream [Ca2+]i mobilization from internal stores
[57,58]. Our data, showing that intracellular Ca2+ depletion
with thapsigargin impaired quinacrine dye destaining
induced by bradykinin is in favor with the hypothesis
that Ca2+ mobilization is necessary for ATP release in
these cells. Further experiments are required to discard the
ability of bradykinin, like certain Gq-coupled receptors,
to additionally stimulate Rho-GTPase acting to strongly
potentiate a Ca2+-activated ATP release pathway [59,60].
Seminario-Vidal and col. (2009) [60], demonstrated that
Ca2+- and RhoA/Rho kinase-dependent ATP release from
thrombin-stimulated A549 lung epithelial cells occurs via
connexin or pannexin hemichannels, a pathway that seems
to be not competent for ATP release in human astrocytoma
cells [59]. Given the actions exerted by Rho/Rho kinase on
cytoskeleton components (e.g. regulating myosin-light chain
phosphorylation and actin polymerization), those authors
speculated that Rho-promoted membrane-cytoskeletal
rearrangements facilitate the insertion of hemichannel
subunits within the plasma membrane.
Bradykinin can increase glutamate release from mouse
astrocytes through volume-sensitive outwardly rectifying
(VSOR) anion channels without cell swelling via a
mechanism that is regulated by high intracellular Ca2+
in nanodomains [61]. Although we did not test directly
whether this pathway plays a role in bradykinin-induced
[Ca2+]i-dependent ATP release from human subcutane-
ous fibroblasts, it appears that VSOR currents would ex-
hibit a slow activation kinetics requiring 15-20 min after
bradykinin application to reach a sustained plateau [61].
This activation pattern is entirely different from the
rapid (within 30 s) ATP releasing response to bradykinin
observed in human fibroblasts (see Figure 3), thus indi-
cating that slow activating but prolonged VSOR cur-
rents play a minor, if some, role in the release of ATP
in our experimental time frame. In our hands mefloquine
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anion channels, failed to modify bradykinin-induced [Ca2+]i
signals. Moreover, modulation of VSOR channel permeabil-
ity through the activation of protein kinase C with the
phorbol ester (12-myristate 13-acetate, 1-10 μM, n = 3) did
not mimic the effect of bradykinin.
Involvement of soluble signaling mediators, such as ATP
and/or its metabolites, may also explain heterogeneity
of individual [Ca2+]i responses to bradykinin within a cell
population; confocal microscopy studies showed that some
cells displayed no plateau phase whereas others were not
noticeably affected by bradykinin removal and continued
to respond for a few minutes (see Figure 1C). This is con-
sistent with the generation of concentration gradients by
released ATP and metabolites formation (namely ADP)
via ectonucleotidases, which enables differential targeting
of subtype-specific P2 purinoceptors and, thus, cell-to-cell
communication depending on proximity. Therefore, we
may speculate that bradykinin-stimulated fibroblasts trigger
a “purinergic wave” mediated by released ATP and metabo-
lites formation that can affect sensory afferent nerve end-
ings localized in the vicinity, representing the first insights
of a fibroblast-neuron communication unproved so far.
Recently, it has been reported that mechanical stimula-
tion of human epidermal keratinocytes induces propagating
Ca2+ waves depending on non-vesicular release of ATP
through connexin hemichannels [48]. In view of the poten-
tial contribution of the cutaneous release of ATP to acute
and chronic pain syndromes, this and other groups demon-
strated that human epidermal keratinocytes co-cultured
with neurons of the dorsal root ganglia interplay through
the release of ATP following keratinocytes-born [Ca2+]i
waves [62]. Likewise, subcutaneous inflammation or injec-
tion of ATP causes pain sensation through the activation of
P2X3 receptors expressed in sensory nerve endings, which
may become sensitized in both animal models and human
patients [63,64]. Knocking down or selectively antagonizing
P2X3 receptor activity results in reduced responses to ATP,
as well as reduced thermal and mechanical hyperalgesia in
inflammatory and neuropathic pain rat models [65,66]. P2Y
purinoceptors, especially P2Y1 and P2Y2, expressed in pri-
mary sensory endings have also been implicated in chronic
pain states [62]. Authors from the latter study agree that
cutaneous ATP release does not appear to contribute to
pain sensation in the absence of tissue injury. However,
under chronic painful conditions, such as inflammation
and nerve injury, nerve endings may become sensitized and
a normally innocuous level of subcutaneous ATP may now
be sufficient to reach the firing threshold of nociceptors
[67]. Despite direct modulation of nociceptors threshold by
ATP released from different cell types may play a key role
to the association between subcutaneous connective tissue
injury and musculoskeletal pain, there are alternative mech-
anisms that should also be considered in this context.These include interference with muscle tension due to fusi-
motor effects induced by group III and IV afferents activa-
tion, which by projecting to γ-motoneurons amplify muscle
spindles activity and, thereby, increases muscle tone, gener-
ating metabolites (e.g. bradykinin) that enter in a positive
feedback loop (reviewed by [41,42,68]).
In addition, it has been proposed that mechanical de-
formation of the skin by needles and application of heat
or electrical current leads to release of large amounts of
ATP from keratinocytes, fibroblasts and other cells in skin
[46]. Impulses generated by P2 purinoceptors in sensory
fibers in the skin connect with interneurons that may
negatively modulate neural pathways to the pain centers
in the cortex. This is the basis for the novel hypothesis for
the involvement of purinergic signaling in acupuncture
[46]. Furthermore, purines are known to cause intracellular
Ca2+-dependent transient changes in cultured human
fibroblast cytoarchitecture, which share similarities with
the increase in cross-sectional area of fibroblasts in
response to acupuncture [69]. Although evidence has
been presented of the role of adenosine in acupuncture-
mediated anti-nociception by demonstrating that the local
concentrations of the nucleoside increase in human
subjects [70] and that adenosine is implicated in the
proliferation of fibroblasts and remodeling of the skin,
liver and lung (reviewed in [37], we failed to demonstrate
any contribution of the nucleoside to bradykinin-induced
[Ca2+]i signals in cultured human subcutaneous fibroblasts.
Controversy still exists regarding adenosine participation in
wound healing and scarring. For instance, the adenosine
A2A receptor promotes skin fibrosis and scarring [71] and
increases collagen production in human dermal fibroblasts
[72] probably by activating the Gs/cyclicAMP pathway [73],
yet it remains controversial how A2A receptors increase col-
lagen production since cyclicAMP has been found to de-
crease the synthesis of collagen and DNA by fibroblasts
[74]. Thus, further studies are required to test long-term ef-
fects of extracellular adenosine, which may originate from
the hydrolysis of ATP released from fibroblasts stimulated
either mechanically (e.g. acupuncture) or by inflammatory
mediators, such as bradykinin. Our findings demonstrating
that adenosine accumulates as an end product of the
catabolism of released ATP in the vicinity of fibroblasts
within the subcutaneous connective tissue may be of
clinical relevance, given the role of the nucleoside on
dermal fibrosis (via A2A receptors) and its anti-nociceptive
properties (via A1 receptors) on free nerve endings and
sensory afferents (reviewed in [37,75]).
Conclusions
Data indicate that stimulation of constitutively expressed
B2 receptors with bradykinin elicits the opening of hemi-
channels containing Cx43 and Panx1 subunits, followed
by ATP diffusion out of human subcutaneous fibroblasts.
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membrane-bound ectonucleotidases acting in an auto-
crine or paracrine way on plasma membrane P2Y12
purinoceptors may contribute to sustain elevated [Ca2+]i
levels in neighboring cells. Thus, targeting the pathways
leading to nucleotides release and the purinergic cascade
in human fibroblasts of the subcutaneous tissue may be
useful in designing novel therapeutic strategies for tuning
the communication between inflammatory cells, fibro-
blasts and sensory nerve endings, which are key players in
the pathogenesis of painful musculoskeletal diseases with
widespread involvement of the subcutaneous connective
tissue (e.g. fibromyalgia).
Methods
Cell cultures
Human fibroblasts were isolated from the subcutaneous
tissue of organ donors (51 ± 6 years old (mean ± S.E.M.),
n = 13) with no clinical history of connective tissue disor-
ders. The protocol was approved by the Ethics Committee
of Centro Hospitalar do Porto (University Hospital) and of
Instituto de Ciências Biomédicas de Abel Salazar (Medical
School) of University of Porto (approval No. 11-CES-05).
The investigation conforms to the principles outlined in
the Declaration of Helsinki. Subcutaneous tissues were
maintained at 4-6°C in M-400 transplantation solution
(4.190 g/100 mL mannitol, 0.205 g/100 mL KH2PO4,
0.970 g/100 mL K2HPO4 · 3H2O, 0.112 g/100 mL KCl, and
0.084 g/100 mL NaHCO3, pH 7.4) until used, which was
between 2 and 16 hours after being harvested [76]. Cells
were then obtained by the explant technique and cultured
in DMEM medium supplemented with 10% fetal bovine
serum (FBS), 2.5 μg/mL of amphotericin B and 100 U/mL
of penicillin/streptomycin, at 37°C in a humidified atmos-
phere of 95% air and 5% CO2. Medium was replaced twice
a week. Primary cultures were maintained for 3-4 weeks,
until near confluence, when adherent cells were enzy-
matically released with 0.04% trypsin-EDTA solution
plus 0.025% type I collagenase in phosphate-buffered saline
(PBS), at pH 7.4 during 15-20 minutes. The resultant
cell suspension was cultured and maintained in the
same conditions mentioned above. All the experiments
were performed in the first subculture.
Intracellular ATP imaging by quinacrine staining
Quinacrine is a weak-base acridine derivative that binds
ATP with high affinity and specificity. When excited by
light at 476 nm it emits fluorescence in the 500-540 nm
range and it has been widely used to visualize ATP-
containing sub-cellular compartments in living cells
[77,78]. Human fibroblasts were seeded on 35 mm glass
bottom dishes (FluoroDish®, World Precision Instruments),
at a density of 2x104 cells/mL, and maintained in culture
for 5-15 days. To visualize ATP-filled vesicles, disheswere washed twice with Tyrode’s solution (137 mM NaCl,
2.7 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 0.4 mM
NaH2PO4, 11.9 mM NaHCO3, and 11.2 mM glucose,
pH 7.4) before incubation with 30 μM quinacrine for
1 h [78]; cells were washed again twice and mounted
onto a thermostatic (32°C) perfusion chamber at the
stage of an inverted laser-scanning confocal microscope
(Olympus FluoViewTM FV1000) equipped with a 40x
magnification oil immersion objective lens (UPLAPO
40x OI; NA: 1.00). The chamber was continuously
superfused (1 mL/min) with gassed (95% O2 + 5% CO2,
pH 7.4) Tyrode’s solution and the cells were immedi-
ately observed. Changes in quinacrine fluorescence
were detected in the time-lapse mode with FluoView
Advanced Software (Olympus). Quinacrine was excited
with a 488 nm Multi-line Ar laser and the emitted fluores-
cence was detected at 500-550 nm, using the scanner of
the confocal microscope. Drugs were delivered using a
multichannel perfusion system (ValveLink 8.2, Digitimer).
Time-lapse sequences were recorded at scanning rates of
3 seconds per image, every 5 seconds, for about 30 mi-
nutes, digitized, and processed off-line by the computer.
Regions of interest were defined as bright areas with as lit-
tle background as possible.
Extracellular ATP quantification by bioluminescence
Extracellular ATP was detected with the luciferin-
luciferase ATP bioluminescence assay kit HS II (Roche
Applied Science) using a Turner BioSystems (TD 20/20n)
luminometer that accommodates 35-mm culture dishes,
as described elsewhere [79]. Briefly, cells were seeded on
35 mm glass bottom dishes, at a density of 2x104 cells/mL,
for 5-15 days. At the beginning of the experiment,
cells were washed twice with Tyrode’s solution at room
temperature, before placing the dish in the luminometer
reaction chamber. Bradykinin (30 μM) was added manu-
ally to the incubation fluid when bioluminescence baseline
values reached stability after application of the luciferin/
luciferase reagent. Experiments were performed at room
temperature. ATP-dependent changes in extracellular lucif-
erase activity were measured as relative luminescence unit
(RLU) values integrated over 10 s photon counting periods.
Measurement of intracellular Ca2+
Changes in the intracellular Ca2+ concentration ([Ca2+]i)
were measured with the calcium sensitive dye Fluo-4
NW (Fluo-4 NW calcium assay kit, Molecular Probes,
Invitrogen) in a multi detection microplate reader
(Synergy™ HT Multi-Mode Microplate Reader, BioTek
Instruments) [80]. In some of the experiments, single-cell
[Ca2+]i imaging was obtained using a laser scanning
confocal microscope [22]. Briefly, human fibroblasts were
seeded in flat bottom 96 well plates (Costar®, Corning® Inc.)
at a density of 3x104 cells/mL for the experiments using the
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density of 2x104 cells/mL for single-cell [Ca2+]i imaging.
Cells were cultured for 5-15 days in supplemented DMEM
as described before. On the day of the experiment, cells
were washed twice with Tyrode’s solution and incubated at
37°C for 45 min with the cell-permeant fluorescent Ca2+
indicator, Fluo-4 NW (2.5 μM), in 1X HBSS, 20 mM
HEPES and 2.5 mM probenecid. After removal of the
fluorophore loading solution, cells were washed again
twice and 150/300 μL of Tyrode’s solution was added per
culture well/dish, respectively. The 96-well cell plates were
then loaded into the microplate reader. Reader control
was performed using the BioTek’s Gen5™ Data Analysis
Software. For the recordings, temperature was maintained
at 32°C and readings were made with 5 seconds of inter-
val, during approximately 30 minutes, using a tungsten
halogen lamp. Fluorescence was excited at 485/20 nm and
emission was measured at 528/20 nm. For the single-cell
imaging, culture dishes were mounted on a thermostatic
(32°C) perfusion chamber at the stage of an inverted laser-
scanning confocal microscope equipped with a 20x mag-
nification objective lens (LUCPLFLN 20x PH; NA: 0.45).
The chamber was continuously superfused (1 mL/min)
with gassed (95% O2, 5% CO2, pH 7.4) Tyrode’s solution
and drugs were delivered using a multichannel valve
controlled perfusion system. Changes in fluorescence
of the Fluo-4 NW dye were detected in a time-lapse
mode. Fluo-4 NW was excited with a 488 nm Multi-line
Ar laser and the emitted fluorescence was detected at
510-560 nm, using the scanner of the confocal micro-
scope. Time-lapse sequences were recorded at scanning
rates with 20 seconds of interval for approximately 30 min,
digitized, and processed off-line by the computer. Regions
of interest were defined as bright areas with as little
background as possible. For both methods, calcium
measurements were calibrated to the maximal calcium load
produced by ionomycin (5 μM, 100% response). In some
experiments, we used rat subcutaneous fibroblasts obtained
using the method described before to monitor single-cell
[Ca2+]i oscillations (see above) in parallel with the incorpor-
ation of FM4-64 (Molecular Probes, Invitrogen), which is a
membrane-selective fluorescent dye used to evaluate vesicle
endocytosis and exocytosis in living cells [33,34]. FM4-64
was excited with a 488 nm Multi-line Ar laser and fluor-
escence emission was detected at 665-765 nm, using the
scanner of the confocal microscope. Drug application and
time-lapse sequences were performed as above.
Enzymatic kinetic experiments and HPLC analysis
The kinetics of ATP, ADP and AMP hydrolysis in human
fibroblast cell cultures was evaluated at day 11, at 37°C.
After a 30-min equilibration period, cells were incubated
with 3 μM ATP, ADP or AMP, which were added to the cul-
ture medium at zero time. Samples (75 μl) were collectedfrom each well at different times up to 30 min for high-
performance liquid chromatography (HPLC, LaChrome
Elite, Merck) analysis of the variation of substrate dis-
appearance and product formation [22,76]. Concentra-
tions of the substrate and products were plotted as a
function of time (progress curves). The following pa-
rameters were analyzed for each progress curve: half-life
time (t1/2) of the initial substrate, time of appearance of
the different concentrations of the products, concentration
of the substrate or any product remaining at the end of
the experiment.
Immunocytochemistry
Human subcutaneous fibroblasts were seeded in chamber
slides at a density of 2.5x104 cells/mL and allowed to grow
for 5-15 days. Cultured cells were fixed in 4% paraformal-
dehyde (PFA) in PBS for 10 minutes, washed 3 times in
PBS (10 minutes each) and, subsequently, incubated with
blocking buffer I (10% FBS, 1% bovine serum albumin
(BSA), 0.1% Triton-X, 0.05% NaN3) for 1 h. Primary anti-
bodies, diluted in blocking buffer II (5% FBS, 1% BSA, 0.1%
Triton-X, 0.05% NaN3), were applied [mouse anti-porcine
vimentin 1:75 (DAKO); rabbit anti-human collagen I
1:50 (AbDSerotec); mouse anti-human α-smooth muscle
actin-FITC 1:250 (Sigma-Aldrich); rabbit anti-human P2Y12
1:100 (Alomone); rabbit anti-human Cx43 1:600 and
rabbit anti-human Panx1 1:1000 (Abcam)] and the slides
incubated overnight at 4°C. After incubation, cells were
washed 3 times in PBS 1X (10 minutes each). The Alexa
Fluor 488 1:1500 (anti-rabbit) and Alexa Fluor 568 1:1500
(anti-mouse) secondary antibodies (Molecular Probes,
Invitrogen) were diluted in blocking buffer II (5% FBS,
1% BSA, 0.1% Triton-X) and applied for 1 h protected
from light. A last wash was performed with PBS 1X and
glass slides were mounted with VectaShield medium and
stored at 4°C. For negative controls, the secondary anti-
bodies were applied without pre-incubation with primary
antibodies. A positive control for α-smooth muscle actin
(SMA) was performed with cardiac myofibroblasts isolated
from Wistar rats (Charles River, Barcelona) using a similar
procedure as previously described for human subcutaneous
fibroblasts. Observations were performed and analyzed
with a laser-scanning confocal microscope [22].
SDS–PAGE and Western blotting
Fibroblasts were homogenized in a lysis buffer with the
following composition: 50 mM Tris-HCl (pH 8.0), 150 mM
NaCl, 0.5% sodium deoxycholate, 1% Triton-X-100, 0.1%
SDS and a protease inhibitor cocktail. Protein content of
the samples was evaluated using the BCA protein assay kit
according to the manufacturer’s instructions (Pierce). Sam-
ples were solubilized in SDS reducing buffer (0.125 mM
Tris-HCl, 4% SDS, 0.004% bromphenol blue, 20% glycerol,
and 10% 2-mercaptoethanol, pH 6.8 at 70°C for 10 min),
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gels and electrotransferred onto PVDF membranes
(MilliPore). Protein loads were 25 μg for Panx1 and
15 μg for Cx43. The membranes were blocked for 1 h
in Tris-buffered saline (TBS: 10 mM Tris-HCl, pH 7.5,
150 mM NaCl) containing 0.05% Tween 20 + 5% BSA.
Membranes were subsequently incubated with rabbit
anti-human Panx1 1:250 (Novex, Life Technologies)
and rabbit anti-human Cx43 1:6000 (Abcam) in the
above blocking buffer overnight at 4ºC. Membranes
were washed three times for 10 min in 0.1% Tween 20
in TBS and then incubated with donkey anti-rabbit
IgG (HRP) 1:30000 (Abcam) secondary antibody, for
60 min at room temperature. For comparison purpose, the
membranes were also incubated with rabbit anti-human
β-tubulin 1:2500 (Abcam) antibody following the procedures
described above. Membranes were washed three times
for 10 min and antigen-antibody complexes were visual-
ized by chemiluminescence with an ECL reagent using the
ChemiDoc MP imaging system (Bio-Rad Laboratories).
Reagents and materials
2-Mercaptoethanol, 2-octanol, 8-phenyltheophylline (8-PT),
adenosine 5’-diphosphate sodium salt (ADP), adenosine
5’-monophosphate sodium salt (AMP), adenosine 5’-
triphosphate sodium salt (ATP), amphotericin B, apyrase,
bovine serum albumin (BSA), bradykinin (BK), brefeldin
A (BFA), bromphenol blue, carbenoxolone (CBX),
Dulbecco’s Modified Eagle’s Medium (DMEM), ethylene
diaminetetraacetic acid (EDTA), ethylene glycol-bis(2-
aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA), fetal
bovine serum (FBS), glycerol, mefloquine (MFQ), 5’-
(N-ethylcarboxamide)adenosine (NECA), penicillin/strepto-
mycin, phosphate buffered saline system (PBS), protease
inhibitor cocktail, quinacrine dihydrochloride, sodium
deoxycholate, sodium dodecyl sulfate (SDS), trypsin,
Tween 20, and type I collagenase were purchased from
Sigma-Aldrich. 10Panx, 2-(propylthio)adenosine-5’-O-
(β,γ-difluoro methylene) triphosphate tetrasodium salt
(AR-C 66096), 2-[(2-chloro-5-nitrophenyl)azo]-5-hy-
droxy-6-methyl-3-[(phosphonooxy)methyl]-4-pyridine
carboxaldehyde disodium salt (MRS 2211), 2’-deoxy-
N6-methyladenosine 3’,5’-bisphosphate tetrasodium
salt (MRS 2179), icatibant (HOE-140), R715, sodium
metatungstate (POM-1) and thapsigargin were obtained
from Tocris Cookson Inc.. Bafilomycin A1 was from
WAKO Chemicals and Triton™ X-100 was obtained from
Merck. BFA, MFQ, NECA and thapsigargin were prepared
in dimethyl sulfoxide (DMSO). All other drugs were pre-
pared in distilled water. All stock solutions were stored as
frozen aliquots at -20°C. Dilutions of these stock solutions
were made daily and appropriate solvent controls were
done. No statistically significant differences between con-
trol experiments, made in the absence or in the presenceof DMSO at the maximal concentration used (0.05% v/v),
were observed. The pH of the solutions did not change by
the addition of the drugs in the maximum concentrations
applied to the preparations.
Presentation of data and statistical analysis
Data are expressed as mean ± S.E.M. from an n number of
experiments/cells/individuals. Data from different indi-
viduals were evaluated by one-way analysis of variance
(ANOVA) and no significant differences on the pattern
of cell behavior were found. Statistical differences found
between control and drug-treated cultures were determined
by the Bonferroni’s method. p values < 0.05 were considered
to represent significant differences.
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